Earnings Reporting: Analysis and Sernova Corp. (SVA) Earnings ReviewJanuary 15, 2017 - By Darrin BlackWall Street await Sernova Corp. (CVE:SVA) to release earnings on January, 16. Sernova Corp. (CVE:SVA) has risen 6.00% since December 16, 2016 and is uptrending. Sernova Corp. is a regenerative medicine firm engaged in the research and development of its Cell Pouch and associated technologies, including therapeutic cells. SVA Company ProfileSinovac Biotech Ltd. (Sinovac), incorporated on March 1, 1999, is a holding company. The Firm is engaged in developing various products, including Healive, Bilive, Anflu, Panflu Whole Viron Pandemic Influenza Vaccine, Split Viron Pandemic Influenza Vaccine, Panflu.1, RabEnd, Mumps Vaccine, Enterovirus 71 (EV71) Vaccine, Pneumococcal Polysaccharide Vaccine, Pneumococcal Conjugate Vaccine, Rubella Vaccine, Varicella Vaccine and Sabin Inactivated Polio Vaccine.

Source: Wall Street Journal January 15, 2017 13:03 UTC